Literature DB >> 2138931

Cyclophosphamide and abrogation of tumor-induced suppressor T cell activity.

S K Hoover1, S K Barrett, T M Turk, T C Lee, H D Bear.   

Abstract

Previously we have demonstrated that the in vitro generation of P815-specific anti-tumor cytotoxic T lymphocytes (CTL) was suppressed by splenic suppressor T cells from late tumor-bearing hosts (TBH). Suppression is not caused by in vitro growth of P815 from splenic metastases, since suppression was also seen with spleen cells from late TBH mice bearing a hypoxanthine/aminopterin/thymidine-sensitive subline (PHS-5) of P815 in the presence of HAT. Cyclophosphamide has been shown to inhibit the induction of suppressor cells selectively in a number of immune responses, but evidence that it can inhibit active tumor-induced suppressor T cells is limited. We have found that suppressor T cells already induced by P815 in syngeneic late TBH are sensitive to low doses of cyclophosphamide (50 mg/kg) given 1 day before spleen harvest, but the in vitro CTL response of late TBH spleen cells could not be restored by pretreating the mice with cyclophosphamide, even when exogenous interleukin-2 was added to the cultures. Although 50 mg/kg cyclophosphamide did not inhibit the CTL response of spleen cells from mice immunized with P815 + Corynebacterium parvum, the same dose of cyclophosphamide eliminated the CTL response of spleen cells from early TBH. Interleukin-2 (IL-2) did not overcome this effect of cyclophosphamide, suggesting a direct effect on CTL. "Ultra-low" -dose cyclophosphamide (10 mg/kg) did not adversely effect early TBH CTL but was still able to eliminate suppressor T cell activity from late TBH. Nevertheless, late TBH CTL remained unresponsive after pretreatment of mice with ultra-low-dose cyclophosphamide, even when exogenous IL-2 was added in vitro. CTL precursor frequency analyses demonstrated that cyclophosphamide pretreatment had little or no effect on the numbers of CTL precursors from early TBH. Late TBH CTL precursor cells were not detectable in these studies, with or without suppressor T cell inhibition by cyclophosphamide pretreatment. Thus, it appears that most CTL precursor cells may be lost or irretrievably inactivated in the spleens of late TBH mice.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2138931     DOI: 10.1007/bf01742376

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  30 in total

1.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

2.  Regulation of the expression of adoptive tumor rejection immunity by recipient cyclophosphamide-sensitive cells.

Authors:  C M Boyer; J W Kreider; G L Bartlett
Journal:  Cancer Res       Date:  1982-06       Impact factor: 12.701

3.  Relative susceptibilities of T cell subsets involved in delayed-type hypersensitivity to sheep red blood cells to the in vitro action of 4-hydroperoxycyclophosphamide.

Authors:  S H Kaufmann; H Hahn; T Diamantstein
Journal:  J Immunol       Date:  1980-09       Impact factor: 5.422

4.  Impairment of concanavalin A-inducible suppressor activity following administration of cyclophosphamide to patients with advanced cancer.

Authors:  D Berd; H C Maguire; M J Mastrangelo
Journal:  Cancer Res       Date:  1984-03       Impact factor: 12.701

5.  Production of tumor-specific suppressor T cell hybridomas.

Authors:  H D Bear
Journal:  J Surg Res       Date:  1987-04       Impact factor: 2.192

6.  Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden.

Authors:  M Awwad; R J North
Journal:  Immunology       Date:  1988-09       Impact factor: 7.397

7.  Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.

Authors:  R J North
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

8.  Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses.

Authors:  P W Askenase; B J Hayden; R K Gershon
Journal:  J Exp Med       Date:  1975-03-01       Impact factor: 14.307

9.  Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells.

Authors:  P D Greenberg; D E Kern; M A Cheever
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

10.  Characterization of cells from invaded lymph nodes in patients with solid tumors. Lymphokine requirement for tumor-specific lymphoproliferative response.

Authors:  F Cozzolino; M Torcia; A M Carossino; R Giordani; C Selli; G Talini; E Reali; A Novelli; V Pistoia; M Ferrarini
Journal:  J Exp Med       Date:  1987-08-01       Impact factor: 14.307

View more
  20 in total

1.  Synergy of brief activation of CD8 T-cells in the presence of IL-12 and adoptive transfer into lymphopenic hosts promotes tumor clearance and anti-tumor memory.

Authors:  C Marcela Díaz-Montero; Osama Naga; Abdel-Aziz A Zidan; Mohamed L Salem; Maria Pallin; Anita Parmigiani; Gail Walker; Eric Wieder; Krishna Komanduri; David J Cole; Alberto J Montero; Mathias G Lichtenheld
Journal:  Am J Cancer Res       Date:  2011-08-30       Impact factor: 6.166

2.  Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.

Authors:  E Proietti; G Greco; B Garrone; S Baccarini; C Mauri; M Venditti; D Carlei; F Belardelli
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

3.  In vivo cyclophosphamide and IL-2 treatment impedes self-antigen-induced effector CD4 cell tolerization: implications for adoptive immunotherapy.

Authors:  Marianne A Mihalyo; Amy D H Doody; Jeremy P McAleer; Elizabeth C Nowak; Meixiao Long; Yi Yang; Adam J Adler
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

4.  The influence of cyclophosphamide on antitumor immunity in mice bearing late-stage tumors.

Authors:  F Culo; I Klapan; T Kolak
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

5.  Importance in timing of cyclophosphamide on the enhancement of interleukin-2-induced cytolysis.

Authors:  E Katsanis; M A Bausero; A C Ochoa; C M Loeffler; B R Blazar; A S Leonard; P M Anderson
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 6.  Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccination.

Authors:  Mohamed Labib Salem; David J Cole
Journal:  Cancer Immunol Immunother       Date:  2009-11-18       Impact factor: 6.968

7.  Enhancement of cytotoxic T lymphocyte growth from spleens of P815-tumor-bearing host mice with mafosfamide.

Authors:  T H Inge; S K Hoover; J L Frank; T T Kawabata; K P Bethke; H D Bear
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

8.  Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C).

Authors:  Mohamed L Salem; C Marcela Díaz-Montero; Amir A Al-Khami; Sabry A El-Naggar; Osama Naga; Alberto J Montero; Ahmed Khafagy; David J Cole
Journal:  J Immunol       Date:  2009-02-15       Impact factor: 5.422

9.  Ability of low-dose cyclophosphamide to overcome metastasis-induced immunosuppression.

Authors:  T M Tuttle; M D Fleming; P S Hogg; T H Inge; H D Bear
Journal:  Ann Surg Oncol       Date:  1994-01       Impact factor: 5.344

10.  Characterization of the exogenous interleukin-2 requirements for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers.

Authors:  M Rubin; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.